Company intelligence / Profile preview
Caribou Biosciences
Berkeley, California, United Statescariboubio.gcs-web.com ↗
- Ownership
- Public · CRBU
- Employees
- ~150
- Development stage
- Phase 1
01
Overview
Caribou’s lead program CB‑010 is the first allogeneic anti-CD19 CAR-T therapy in the clinic with a PD‑1 knockout for improved antitumor activity. Early clinical data from ongoing Phase 1 trials show promising safety and efficacy signals. Additional programs targeting multiple myeloma and AML are also in early clinical development. The company’s proprietary chRDNA platform enables highly specific multiplex gene editing to armor cells against immune rejection and exhaustion[7][9].
- Therapeutic areas
- Oncology
- Modalities
- Allogeneic CAR-T cell therapiesAllogeneic CAR-NK cell therapies (preclinical)Genome-edited cell therapies using CRISPR-Cas9 and Cas12a with chRDNA guides[1][4][5][6]
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
AbbVie Inc.ProMab BiotechnologiesMaxCyte Inc.Pfizer Inc. ($25 million equity investment in July 2023)[4][5][7]
04
Financials
- Market cap
- $142.8M
- Total revenue
- $1.5M
- Enterprise value
- $57.2M
Beyond the preview
Go deeper on Caribou Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caribou Biosciences.